Irene Konstantopoulou

List of Publications by Year
in descending order

91	5,545	117625	85541
papers	citations	34 h-index	71 g-index

95	95	95	8527
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
2	Lung cancer as a predominant feature in a patient with <scp>Peutzâ€“Jeghers</scp> syndrome: Case report. Thoracic Cancer, 2022, , .	1.9	2
3	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
4	Pitfalls in variant annotation for hereditary cancer diagnostics: The example of IlluminaÂ® VariantStudioÂ®. Genomics, 2021, 113, 748-754.	2.9	0
5	CHEK2 Pathogenic Variants in Greek Breast Cancer Patients: Evidence for Strong Associations with Estrogen Receptor Positivity, Overuse of Risk-Reducing Procedures and Population Founder Effects. Cancers, 2021, 13, 2106.	3.7	5
6	The predictive ability of the 313 variantâ€“based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. Genetics in Medicine, 2021, 23, 1726-1737.	2.4	16
7	CanVaS: Documenting the genetic variation spectrum of Greek cancer patients. Human Mutation, 2021, 42, 1081-1093.	2.5	1
8	When cascade testing for familial variant seems inadequate to provide clinically actionable information for blood relatives. Cancer Genetics, 2021, 258-259, 49-50.	0.4	1
9	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
10	Pathology of BRCA1- and BRCA2-associated Breast Cancers: Known and Less Known Connections. Clinical Breast Cancer, 2020, 20, 152-159.	2.4	9
11	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
12	Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology, 2020, 38, 674-685.	1.6	270
13	Pathogenic Variants in Breast Cancer Susceptibility Genes in Older Women. JAMA - Journal of the American Medical Association, 2020, 324, 397.	7.4	0
14	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
15	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
16	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
17	The Spectrum of FANCM Protein Truncating Variants in European Breast Cancer Cases. Cancers, 2020, 12, 292.	3.7	11
18	Variant Interpretation in Patients With Metastatic Breast Cancer. JAMA Oncology, 2020, 6, 581.	7.1	0

#	Article	IF	Citations
19	BRCA1 and BRCA2 germline testing in Cretan isolates reveals novel and strong founder effects. International Journal of Cancer, 2020, 147, 1334-1342.	5.1	7
20	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
21	The spectrum of BRCA1 and BRCA2 pathogenic sequence variants in Middle Eastern, North African, and South European countries. Human Mutation, 2019, 40, e1-e23.	2.5	34
22	Prevalence and founder effect of the BRCA1 p.(Val1833Met) variant in the Greek population, with further evidence for pathogenicity and risk modification. Cancer Genetics, 2019, 237, 90-96.	0.4	7
23	A Patient Affected with Serous Ovarian/Peritoneal Carcinoma Carrying the FANCM Mutation. Case Reports in Oncological Medicine, 2019, 2019, 1-2.	0.3	1
24	PALB2 c.2257C>T truncating variant is a Greek founder and is associated with high breast cancer risk. Journal of Human Genetics, 2019, 64, 767-773.	2.3	8
25	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
26	Functional characterization of CHEK2 variants in a Saccharomyces cerevisiae system. Human Mutation, 2019, 40, 631-648.	2.5	34
27	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
28	Germline deleterious mutations in genes other than BRCA2 are infrequent in male breast cancer. Breast Cancer Research and Treatment, 2018, 169, 105-113.	2.5	37
29	Genetic analysis and clinical description of Greek patients with Peutz-Jeghers syndrome: Creation of a National Registry. Cancer Genetics, 2018, 220, 19-23.	0.4	12
30	Extending the clinical phenotype associated with biallelic NTHL1 germline mutations. Clinical Genetics, 2018, 94, 588-589.	2.0	23
31	Characterization and prevalence of two novel CHEK2 large deletions in Greek breast cancer patients. Journal of Human Genetics, 2018, 63, 877-886.	2.3	7
32	Triple-Negative Breast Cancer Risk Genes Identified by Multigene Hereditary Cancer Panel Testing. Journal of the National Cancer Institute, 2018, 110, 855-862.	6.3	225
33	Contribution of RAD51D germline mutations in breast and ovarian cancer in Greece. Journal of Human Genetics, 2018, 63, 1149-1158.	2.3	7
34	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. Nature Genetics, 2017, 49, 1767-1778.	21.4	289
35	Haplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation. Clinical Genetics, 2017, 91, 482-487.	2.0	18
36	The fate of BRCA1-related germline mutations in triple-negative breast tumors. American Journal of Cancer Research, 2017, 7, 98-114.	1.4	4

#	Article	IF	Citations
37	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
38	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
39	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
40	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
41	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77
42	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
43	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. Breast Cancer Research, 2015, 17, 61.	5.0	26
44	Assessing Associations between the AURKA-HMMR-TPX2-TUBG1 Functional Module and Breast Cancer Risk in BRCA1/2 Mutation Carriers. PLoS ONE, 2015, 10, e0120020.	2.5	34
45	Inherited Mutations in 17 Breast Cancer Susceptibility Genes Among a Large Triple-Negative Breast Cancer Cohort Unselected for Family History of Breast Cancer. Journal of Clinical Oncology, 2015, 33, 304-311.	1.6	521
46	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
47	CHEK2 c.1100delC allele is rarely identified in Greek breast cancer cases. Cancer Genetics, 2015, 208, 129-134.	0.4	11
48	Genetic evaluation based on family history and Her2 status correctly identifies <scp>TP53</scp> mutations in very early onset breast cancer cases. Clinical Genetics, 2015, 87, 383-387.	2.0	4
49	DNA Glycosylases Involved in Base Excision Repair May Be Associated with Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. PLoS Genetics, 2014, 10, e1004256.	3.5	47
50	A Paternally InheritedBRCA1Mutation Associated with an Unusual Aggressive Clinical Phenotype. Case Reports in Genetics, 2014, 2014, 1-3.	0.2	3
51	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. Breast Cancer Research, 2014, 16, 3416.	5.0	57
52	High prevalence of <scp>BRCA1</scp> founder mutations in Greek breast/ovarian families. Clinical Genetics, 2014, 85, 36-42.	2.0	33
53	Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. Carcinogenesis, 2014, 35, 1012-1019.	2.8	145
54	alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies. BMC Clinical Pathology, 2014, 14, 28.	1.8	13

#	Article	IF	Citations
55	Genetic variation in mitotic regulatory pathway genes is associated with breast tumor grade. Human Molecular Genetics, 2014, 23, 6034-6046.	2.9	12
56	Genome-wide association studies identify four ER negativeâ€“specific breast cancer risk loci. Nature Genetics, 2013, 45, 392-398.	21.4	374
57	Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. PLoS ONE, 2013, 8, e58182.	2.5	27
58	Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Research and Treatment, 2012, 134, 353-362.	2.5	82
59	ENIGMA-Evidence-based network for the interpretation of germline mutant alleles: An international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Human Mutation, 2012, 33, 2-7.	2.5	269
60	A common variant at the TERT-CLPTM1L locus is associated with estrogen receptorâ€“negative breast cancer. Nature Genetics, 2011, 43, 1210-1214.	21.4	279
61	Haplotype analysis of two recurrent genomic rearrangements in the BRCA1 gene suggests they are founder mutations for the Greek population. Clinical Genetics, 2011, 80, 375-382.	2.0	11
62	On the origin and diffusion of BRCA1 c.5266dupC (5382insC) in European populations. European Journal of Human Genetics, 2011, 19, 300-306.	2.8	107
63	Evaluation of the XRCC1 gene as a phenotypic modifier in BRCA1/2 mutation carriers. Results from the consortium of investigators of modifiers of BRCA1/BRCA2. British Journal of Cancer, 2011, 104, 1356-1361.	6.4	7
64	Common Breast Cancer Susceptibility Loci Are Associated with Triple-Negative Breast Cancer. Cancer Research, 2011, 71, 6240-6249.	0.9	109
65	Association of the VariantsCASP8D302H andCASP10V410I with Breast and Ovarian Cancer Risk inBRCA1andBRCA2Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2859-2868.	2.5	37
66	Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. British Journal of Cancer, 2009, 101, 32-37.	6.4	24
67	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. British Journal of Cancer, 2009, 101, 1456-1460.	6.4	19
68	Greek BRCA1 and BRCA2 mutation spectrum: two BRCA1 mutations account for half the carriers found among high-risk breast/ovarian cancer patients. Breast Cancer Research and Treatment, 2008, 107, 431-441.	2.5	38
69	G1738R is a BRCA1 founder mutation in Greek breast/ovarian cancer patients: evaluation of its pathogenicity and inferences on its genealogical history. Breast Cancer Research and Treatment, 2008, 110, 377-385.	2.5	37
70	Novel genomic rearrangements in the BRCA1 gene detected in greek breast/ovarian cancer patients. European Journal of Cancer, 2007, 43, 443-453.	2.8	45
71	A rareRETgene exonÂ8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clinical Endocrinology, 2006, 64, 561-566.	2.4	41
72	Identifying and testing for hereditary susceptibility to breast/ovarian cancer in Serbia: Where are we now?. Archive of Oncology, 2006, 14, 131-135.	0.2	0

#	Article	IF	Citations
73	Ichthyosis Follicularis with Alopecia and Photophobia in a Girl with Cataract: Histological and Electron Microscopy Findings. Acta Dermato-Venereologica, 2005, 85, 51-55.	1.3	12
74	BRCA1 and BRCA2 genes mutation analysis in patients with a family history of breast and ovarian cancer. Journal of Medical Biochemistry, 2004, 23, 271-277.	0.1	3
75	Lack of association between RNASEL Arg462Gln variant and the risk of breast cancer. Anticancer Research, 2004, 24, 2547-9.	1.1	7
76	Atypical Medullary Breast Carcinoma in a Family Carrying the 5382insC BRCA-1 Mutation. Breast Journal, 2003, 9, 260-262.	1.0	6
77	Prelingual Nonsyndromic Hearing Loss in Greece. Orl, 2002, 64, 321-323.	1.1	13
78	Growth index is independent of microvessel density in nonâ€“small-cell lung carcinomas. Human Pathology, 2002, 33, 812-818.	2.0	21
79	Prevalence of GJB2 mutations in prelingual deafness in the Greek population. International Journal of Pediatric Otorhinolaryngology, 2002, 65, 101-108.	1.0	63
80	Germ line BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families: 5382insC is the most frequent mutation observed. Cancer Letters, 2002, 185, 61-70.	7.2	42
81	A change in the last base of BRCA1 exon 23, 5586Gâ†'A, results in abnormal RNA splicing. Cancer Genetics and Cytogenetics, 2002, 134, 175-177.	1.0	19
82	BRCA2 gene mutations in Greek patients with familial breast cancer. Human Mutation, 2002, 19, 81-82.	2.5	35
83	BRCA1 mutation analysis in breast/ovarian cancer families from Greece. Human Mutation, 2000, 16, 272-273.	2.5	27
84	The Heat-Shock Gene hsp83 of Drosophila auraria: Genomic Organization, Nucleotide Sequence, and Long Antiparallel Coupled ORFs (LAC ORFs). Journal of Molecular Evolution, 1998, 46, 334-343.	1.8	16
85	The hsp70 locus of Drosophila auraria (montium subgroup) is single and contains copies in a conserved arrangement. Chromosoma, 1998, 107, 577-586.	2.2	23
86	Variations in the heat-induced protein pattern of severalDrosophila montiumsubgroup species (Diptera: Drosophilidae). Genome, 1997, 40, 132-137.	2.0	4
87	The heat shock genes in theDrosophila montium subgroup: Chromosomal localization and evolutionary implications. Chromosoma, 1996, 105, 104-110.	2.2	20
88	The Afrotropical Drosophila montium subgroup: Balbiani ring 1, polytene chromosomes, and heat shock response of Drosophila vulcana. Genome, 1996, 39, 588-597.	2.0	13
89	The heat shock genes in the Drosophila montium subgroup: chromosomal localization and evolutionary implications. Chromosoma, 1996, 105, 104-110.	2.2	2
90	A Drosophila hsp70 gene contains long, antiparallel, coupled open reading frames (LAC ORFs) conserved in homologous loci. Journal of Molecular Evolution, 1995, 41, 414-420.	1.8	28

#	Article	IF	Citations
91	Insecticidal effects of essential oils. A study of the effects of essential oils extracted from eleven Greek aromatic plants onDrosophila auraria. Experientia, 1992, 48, 616-619.	1.2	152